Enhancing intracellular taxane delivery: current role and perspectives of nanoparticle albumin-bound paclitaxel in the treatment of advanced breast cancer

Bibliography

• Jemal A, Bray F, Center MM, Global cancer statistics. CA Cancer J Clin 2011;61:69-90
   PubMed Web of Science ®Google Scholar
• Howlader N, Noone AM, Krapcho M, editors. SEER Cancer Statistics Review, 1975 – 2008, Bethesda, MD: National Cancer Institute. Based on November 2010 SEER data submission, posted to the SEER website, 2011. Available from: http://seer.cancer.gov/csr/1975_2008/ [Last accessed 5 October 2011]
   Google Scholar
• Guarneri V, Conte P. Metastatic breast cancer: therapeutic options according to molecular subtypes and prior adjuvant therapy. Oncologist 2009;14:645-56
   PubMed Web of Science ®Google Scholar
• Piccart-Gebhart MJ, Burzykowski T, Buyse M, Taxanes alone or in combination with anthracyclines as first-line therapy of patients with metastatic breast cancer. J Clin Oncol 2008;26:1980-6
   PubMed Web of Science ®Google Scholar
• De Laurentiis M, Cancello G, D'Agostino D, Taxane-based combinations as adjuvant chemotherapy for early breast cancer: a meta-analysis of randomized trials. J Clin Oncol 2008;26:44-53
   PubMed Web of Science ®Google Scholar
• Taxol (paclitaxel) Injection [Package Insert]. Brystol-Meyers Squibb Co.; Princeton, NJ: 2003
   Google Scholar
• Taxotere (docetaxel) Injection Concentrate [Package Insert]. Aventis Pharmaceutical Products, Inc.; Bridgewater, NJ: 2003
   Google Scholar
• Ten Tije AJ, Verweij J, Loos WJ, Sparreboom A. Pharmacological effects of formulation vehicles: implications for cancer chemotherapy. Clin Pharmacokinet 2003;42:665-85
   PubMed Web of Science ®Google Scholar
• Weiss RB, Donehower RC, Wiernik PH, Hypersensitivity reactions from taxol. J Clin Oncol 1990;8:1263-8
   PubMed Web of Science ®Google Scholar
• Authier N, Gillet JP, Fialip J, Assessment of neurotoxicity following repeated cremophor/ethanol injections in rats. Neurotox Res 2001;3:301-6
   PubMed Web of Science ®Google Scholar
• Postma TJ, Vermorken JB, Liefting AJM, Paclitaxel-induced neuropathy. Ann Oncol 2004;6:484-94
   Google Scholar
• Gelderblom H, Verweij J, Nooter K, Cremophor EL: the drawbacks and advantages of vehicle selection for drug formulation. Eur J Cancer 2001;37:1590-8
   PubMed Web of Science ®Google Scholar
• Van Zuylen L, Verweij J, Sparreboom A. Role of formulation vehicles in taxane pharmacology. Invest New Drugs 2001;19:125-41
   PubMed Web of Science ®Google Scholar
• Baker J, Ajani J, Scotte F, Docetaxel-related side effects and their management. Eur J Oncol Nurs 2009;13:49-59
   PubMed Web of Science ®Google Scholar
• Sparreboom A, van Zuylen L, Brouwer E, Cremophor EL-mediated alteration of paclitaxel distribution in human blood: clinical pharmacokinetic implications. Cancer Res 1999;59:1454-7
   PubMed Web of Science ®Google Scholar
• Kratz F. Albumin as a drug carrier: design of new drugs, drugs conjugates and nanoparticles. J Control Release 2008;132:171-83
   PubMed Web of Science ®Google Scholar
• Schnitzer JE, Oh P. Albondin-mediated capillary permeability to albumin. Differential role of receptors in endothelial transcytosis and endocytosis of native and modified albumin. J Biol Chem 1994;269:6072-82
   PubMed Web of Science ®Google Scholar
• Tiruppathi C, Song W, Bergenfeldt M, Gp60 activation mediates albumin transcytosis in endothelial cells by tyrosin kinase-dependent pathway. J Biol Chem 1997;272:25968-75
   PubMed Web of Science ®Google Scholar
• Cortes J, Saura C. Nanopartcle albumin-bound (nab™)-paclitaxel: improving efficacy and tolerability by targeted drug delivery in metastatic breast cancer. Eur J Cancer Suppl 2010;8:1-10
   Web of Science ®Google Scholar
• Gradishar WJ. Albumin-bound paclitaxel: a next-generation taxane. Expert Opin Pharmacother 2006;7:1041-53
   PubMed Web of Science ®Google Scholar
• ABRAXANE Healthcare Professional Prescribing Information. 2010. Available from: http://www.abraxane.com/professional/PDF/Abraxane_Healthcare_Professional_Prescribing_Information.pdf [Last accessed 1 October 2011]
   Google Scholar
• Abraxane: EPAR – Product Information. 2011. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000778/WC500020435.pdf [Last accessed 1 October 2011]
   Google Scholar
• Desai NP, Trieu V, Yao Z, Increased antitumor activity, intratumor paclitaxel concentrations, and endothelial cell transport of cremophor-free, albumin-bound paclitaxel, ABI-007, compared with cremophor-based paclitaxel. Clin Cancer Res 2006;12:1317-24
   PubMed Web of Science ®Google Scholar
• Jain RK. Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science 2005;307:58-62
   PubMed Web of Science ®Google Scholar
• Trieu V, Frankel T, Labao E, SPARC expression in breast tumors may correlate to increased tumor distribution of nanoparticle albumin-bound paclitaxel (ABI-007) vs taxol. Proc Am Assoc Cancer Res 2005;46:abstract 5584
   Google Scholar
• Volk LD, Flister MJ, Bivens CM, Nab-paclitaxel efficacy in the orthotopic model of human breast cancer is significantly enhanced by concurrent anti-vascular endothelial growth factor A therapy. Neoplasia 2008;10:613-18
   PubMed Web of Science ®Google Scholar
• Ibrahim NK, Desai N, Legha S, Phase I and pharmacokinetic study of ABI-007, a cremophor-free, protein-stabilized, nanoparticle formulation of paclitaxel. Clin Cancer Res 2002;8:1038-44
   PubMed Web of Science ®Google Scholar
• Nyman DW, Campbell KJ, Hersh E, Phase I and pharmacokinetics trial of ABI-007, a novel nanoparticle formulation of paclitaxel in patients with advanced nonhematologic malignancies. J Clin Oncol 2005;23:7785-93
   PubMed Web of Science ®Google Scholar
• Sparreboom A, Scripture CD, Trieu V, Comparative preclinical and clinical pharmacokinetics of a cremophor-free, nanoparticle albuminbound paclitaxel (ABI-007) and paclitaxel formulated in Cremophor (Taxol). Clin Cancer Res 2005;11:4136-43
   PubMed Web of Science ®Google Scholar
• Gardner ER, Dahut WL, Scripture CD, Randomized crossover pharmacokinetic study of solvent-based paclitaxel and nab-paclitaxel. Clin Cancer Res 2008;14:4200-5
   PubMed Web of Science ®Google Scholar
• Ando M, Yonemori K, Katsumata N, Phase I and pharmacokinetic study of nab-paclitaxel, nanoparticle albumin-bound paclitaxel, administered weekly to Japanese patients with solid tumors and metastatic breast cancer. Cancer Chemother Pharmacol 2011. [Epub ahead of print]
   Web of Science ®Google Scholar
• Ibrahim NK, Samuels B, Page R, Multicenter phase II trial of ABI-007, an albumin-bound paclitaxel, in women with metastatic breast cancer. J Clin Oncol 2005;23:6019-26
   PubMed Web of Science ®Google Scholar
• Gradishar WJ, Krasnojon D, Cheporov S, Significantly longer progression-free survival with nab-paclitaxel compared with docetaxel as first-line therapy for metastatic breast cancer. J Clin Oncol 2009;27:3611-19
   PubMed Web of Science ®Google Scholar
• Gradishar WJ, Krasnojon D, Cheporov S, Albumin-bound paclitaxel (ab-pac) versus docetaxel for first-line treatment of metastatic breast cancer (MBC): Final overall survival (OS) analysis of a randomized phase II trial. J Clin Oncol 2011;29(Suppl 27): abstract 275
   Web of Science ®Google Scholar
• Gradishar WJ, Krasnojon D, Cheporov S, Nab-paclitaxel versus docetaxel for the first-line treatment of metastatic breast cancer: overall survival subset analyses of a randomized phase II trial [abstract 5060]. Presented at the European Multidisciplinary Cancer Congress; 23 – 27 September 2011; Stockholm, Sweden
   Google Scholar
• Blum JL, Savin MA, Edelman G, Phase II study of weekly albumin-bound paclitaxel for patients with metastatic breast cancer heavily pretreated with taxanes. Clin Breast Cancer 2007;7:850-6
   PubMed Web of Science ®Google Scholar
• Gradishar WJ, Tjulandin S, Davidson N, Superior efficacy of albumin-bound paclitaxel, ABI-007, compared with polyethylated castor oil-based paclitaxel in women with metastatic breast cancer: results of a phase III trial. J Clin Oncol 2005;23:1-10
   PubMed Web of Science ®Google Scholar
• Guan Z, Feng F, Li QL, Randomized study comparing nab-paclitaxel with solvent-based paclitaxel in Chinese patients (pts) with metastatic breast cancer (MBC). J Clin Oncol 2007;25(Suppl 18): abstract 1038
   PubMedGoogle Scholar
• Aapro M, Tjulandin S, Bhar P, Gradishar W. Weekly nab-paclitaxel is safe and effective in ≥ 65 years old patients with metastatic breast cancer: A post-hoc analysis. Breast 2011;20:468-74
   PubMed Web of Science ®Google Scholar
• Roy V, LaPlant BR, Gross GG, North Central Cancer Treatment Group. Phase II trial of weekly nab (nanoparticle albumin-bound)-paclitaxel (nab-paclitaxel) (Abraxane) in combination with gemcitabine in patients with metastatic breast cancer (N0531). Ann Oncol 2009;20:449-53
   PubMed Web of Science ®Google Scholar
• Somer BG, Schwartzberg LS, Arena F, Phase II trial of nab-paclitaxel (nanoparticle albumin-bound paclitaxel (ABX)) + capecitabine (XEL) in first-line treatment of metastatic breast cancer (MBC). J Clin Oncol 2007;25(Suppl 18): abstract 1053
   Web of Science ®Google Scholar
• Danso MA, Blum JL, Robert NJ, Phase II trial of weekly nab-paclitaxel in combination with bevacizumab as first-line treatment in metastatic breast cancer. J Clin Oncol 2008;26(Suppl 15):abstract 1075
   PubMedGoogle Scholar
• Lobo C, Lopes G, Baez O, Final results of a phase II study of nab-paclitaxel, bevacizumab and gemcitabine as first-line therapy for patients with HER2-negative metastatic breast cancer. Breast Cancer Res Treat 2010;123:427-35
   PubMed Web of Science ®Google Scholar
• Conlin AK, Hudis CA, Bach A, Randomized phase II trial of nanoparticle albumin-bound paclitaxel in three dosing schedules with bevacizumab as first-line therapy for HER2-negative metastatic breast cancer (MBC). J Clin Oncol 2009;27(Suppl 15):abstract 1006
   Google Scholar
• Conlin AK, Seidman AD, Bach A, Phase II trial of weekly nanoparticle abumin-bound paclitaxel with carboplatin and trastuzumab as first-line therapy for women with HER2-overexpressing metastatic breast cancer. Clin Breast Cancer 2010;10:281-7
   PubMed Web of Science ®Google Scholar
• Mirtsching B, Corsgriff T, Harker G, A phase II study of weekly nanoparticle albumin-bound paclitaxel with or without trastuzumab in metastatic breast cancer. Clin Breast Cancer 2011;11:121-8
   PubMed Web of Science ®Google Scholar
• Winer EP, Berry DA, Woolf S, Failure of higher-dose paclitaxel to improve outcome in patients with metastatic breast cancer: cancer and leukemia group B trial 9342. J Clin Oncol 2004;22:2061-8
   PubMed Web of Science ®Google Scholar
• Green MC, Buzdar AU, Smith T, Weekly paclitaxel improves pathologic complete remission in operable breast cancer when compared with paclitaxel once every 3 weeks. J Clin Oncol 2005;23:5983-92
   PubMed Web of Science ®Google Scholar
• Seidman AD, Berry D, Cirrincione C, Randomized phase III trial of weekly compared with every-3-weeks paclitaxel for metastatic breast cancer, with trastuzumab for all HER-2 overexpressors and random assignment to trastuzumab or not in HER-2 nonoverexpressors: final results of Cancer and Leukemia Group B protocol 9840. J Clin Oncol 2008;26:1642-9
   PubMed Web of Science ®Google Scholar
• ClinicalTrials.gov, Identifier NCT00785291. http://www.clinicaltrial.gov/ct2/show/NCT00785291 [Last accessed 5 October 2011]
   Google Scholar
• IXEMPRA® (ixabepilone) for injection [Prescribing Information]. Princeton, NJ: Bristol-Myers Squibb Co., 2010. Available from: http://packageinserts.bms.com/pi/pi_ixampra.pdf [Last accessed 5 October 2011]
   Google Scholar
• Chan A, Miles D, Pivot X. Bevacizumab in combination with taxanes for the first-line treatment of metastatic breast cancer. Ann Oncol 2010;21:2135-44
   PubMedGoogle Scholar
• Podhajcer OL, Benedetti LG, Girotti MR, The role of the matricellular protein SPARC in the dynamic interaction between the tumor and the host. Cancer Metastasis Rev 2008;27:691-705
   PubMedGoogle Scholar
• Chin D, Boyle GM, Williams RM, Novel markers for poor prognosis in head and neck cancer. Int J Cancer 2005;113:789-97
   PubMed Web of Science ®Google Scholar
• Koukourakis MI, Giatromanolaki A, Brekken RA, Enhanced expression of SPARC/osteonectin in the tumor-associated stroma of non-small cell lung cancer is correlated with markers of hypoxia/acidity and with poor prognosis of patients. Cancer Res 2003;63:5376-80
   PubMed Web of Science ®Google Scholar
• Von Hoff DD, Penny R, Shack S, Frequency of potential therapeutic targets identified by immunohistochemistry (IHC) and DNA microarray (DMA) in tumors from patients who have progressed on multiple therapeutic agents. J Clin Oncol 2006;24(Suppl 18): abstract 3071
   PubMed Web of Science ®Google Scholar
• Watkins G, Douglas-Jones A, Bryce R, Increased levels of SPARC (osteonectin) in human breast cancer tissues and its association with clinical outcomes. Prostaglandins Leukot Essent Fatty Acids 2005;72:267-72
   PubMed Web of Science ®Google Scholar
• Hsiao YH, Lien HC, Hwa HL, SPARC (osteonectin) in breast tumors of different histologic types and its role in the outcome of invasive ductal carcinoma. Breast J 2010;16:305-8
   PubMed Web of Science ®Google Scholar
• Nagai MA, Gerhard R, Fregnani JH, Prognostic value of NDRG1 and SPARC protein expression in breast cancer patients. Breast Cancer Res Treat 2011;12:1-14
   Google Scholar
• Desai NP, Trieu V, Hwang LY, Improved effectiveness of nanoparticle albumin-bound (nab) paclitaxel versus polysorbate-based docetaxel in multiple xenografts as a function of HER2 and SPARC status. Anticancer Drugs 2008;19:899-0
   PubMed Web of Science ®Google Scholar
• Von Hoff D, Ramanathan E, Borad M, SPARC correlation with response to gemcitabine (G) plus nab-paclitaxel (nab-P) in patients with advanced metastatic pancreatic cancer: a phase I/II Study. J Clin Oncol 2009;27(Suppl 15): abstract 4525
   PubMed Web of Science ®Google Scholar
• Inhorn RC, Daniel B, Daniel D, Correlation of SPARC, ER, PR, and HER2 tumor with progression-free survival from a phase II neoadjuvant trial of gemcitabine, epirubicin, and nab-paclitaxel. J Clin Oncol 2009;27(Suppl 15): abstract 618
   Web of Science ®Google Scholar
• Blackwell KL, Hamilton EP, Rocha G, SPARC microenvironment signature (SMS) in patients treated with nab-paclitaxel (nabP)/carboplatin (C)/bevacizumab(B) for triple-negative metastatic breast cancer (TNMBC). J Clin Oncol 2010;28(Suppl 15):abstract e21040
   Web of Science ®Google Scholar
• Robidoux A, Buzdar AU, Quinaux E, A phase II neoadjuvant trial of sequential weekly nanoparticle albumin-bound paclitaxel followed by 5-fluorouracil/epirubicin/cyclophosphamide in locally advanced breast cancer. Clin Breast Cancer 2010;10:81-6
   PubMed Web of Science ®Google Scholar
• Yardley DA, Raefsky E, Castillo R, Results of a multicenter pilot study of weekly nab-paclitaxel, carboplatin with bevacizumab, and trastuzumab as neoadjuvant therapy in HER2+ locally advanced breast cancer with SPARC correlatives. J Clin Oncol 2009;27(Suppl 15): abstract 427
   Web of Science ®Google Scholar